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Amyotrophic lateral sclerosis (ALS) is an adult motor neuron disease characterized by premature death of upper and lower motor
neurons.Two percent of ALS cases are caused by the dominantmutationsin the gene for superoxide dismutase1 (SOD1) through
a gain of toxic property of mutant protein. Genetic and chimeric mice studies using SOD1 models indicate that non-neuronal
cells play important roles in neurodegeneration through non-cell autonomous mechanism. We review the contribution of each
glial cell type in ALS pathology from studies of the rodent models and ALS patients. Astrogliosis and microgliosis are not only
considerablehallmarksofthe disease,but the intensityofmicroglialactivationis correlated withseverity ofmotorneuron damage
in human ALS. The impaired astrocytic functions such as clearance of extracellular glutamate and release of neurotrophic factors
areimplicatedindisease.Further, thedamagewithinastrocytes andmicrogliaisinvolvedinaccelerateddiseaseprogression.Finally,
other glial cells such as NG2 cells, oligodendrocytes and Schwann cells are under the investigation to determine their contribution
in ALS. Accumulating knowledge of active role of glial cells in the disease should be carefully applied to understanding of the
sporadic ALS and development of therapy targeted for glial cells.
1.Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by
premature death of upper and lower motor neurons starting
in adulthood. The pathology of ALS is characterized by
abnormal accumulation of insoluble and misfolded proteins
in degenerating motor neurons. Neuronal death results in
progressive paralysis, which typically is fatal 2–5 years after
the onset due to respiratory failure. Ten percent of ALS
cases are inherited, while the rest are considered sporadic
and the cause has not been discovered yet. Twenty percent
of inherited ALS cases are caused by mutations in the gene
encoding for superoxide dismutase 1 (SOD1) [1, 2]. SOD1,
a ubiquitously expressed enzyme, catalytically converts reac-
tive superoxide to oxygen and hydrogen peroxide. It is
now recognized that all diﬀerent mutations of SOD1 gene
(both enzymatically active and inactive mutants) uniformly
cause toxicity in cells not by loss but rather by gain of
function where accumulation of protein in neurons and glia
causes toxicity. However, the exact mechanism and nature
of toxicity are still unknown [3, 4]. Currently, numerous
mechanisms of toxicity have been proposed that could
mediate pathology in mutant SOD1-mediated ALS. The
most important mechanisms are thought to be excitotoxicity
from glutamate, failure of protein degradation machinery,
ER stress, damage to mitochondria, superoxide generation
through neuroinﬂammation, axonal transport disruption,
andspinalcapillarymicrohemorrhages[5–11].Thereisgood
evidence for all of these mechanisms to be at play, and most
likely it is a combination of diﬀerent events that contribute
to the overall development of ALS pathology.
ThediscoveryofSOD1mutationsledtothedevelopment
of animal models that recapitulate ALS-like disease. Over-
productionof mutated human SOD1protein in these mouse
models leads to a progressive neurodegenerative disease that
closely resembles human pathology with a selective motor
neuron death and gliosis accompanied by accumulation of
misfolded proteins [12].
The selective death of motor neurons initially led the
researchers tobelievethatcellautonomousmechanisms were2 Neurology Research International
at play. However, genetic and chimeric mice studies indicate
that non-cell autonomous processes might underlie motor
neuron loss in these rodent examples and hence potentially
in ALS. First, when expression of SOD1 mutations was
restricted to either motor neurons or astrocytes, but not
in both simultaneously, it did not lead to the development
of ALS [13–15]. A recent study succeeded to produce very
late onset disease in mice when mutant is expressed in all
neurons [16] however, the severity and rapidity of disease
progression of the mice were much more modest compared
with mice expressing the same mutant gene ubiquitously.
Second,wild-type neurons, in chimeric mice with both wild-
type and mutant SOD1-expressing cells, acquired an ALS
phenotype when surrounded by glial cells bearing SOD1
mutation [17]. Finally, removal of mutant SOD1 expression
in either astrocytes or microglia using ﬂoxed SOD1 gene
excised by Cre recombinase slowed the disease progression
and extended life expectancy [18–21]. Immunohistological
studies also show glial cell involvement in ALS pathology
where astrogliosis and microgliosis are considerable hall-
marks of the disease [22, 23]. Among the non-neuronal cell
types, a role of glial cells in ALS has been most intensively
investigated. Here, we review the contribution of each glial
cell type in ALS pathology from studies of the rodent models
and ALS patients.
2.Microglia
Microglia, derived from the hematopoietic cell lineage, are
generally considered as the primary immune cells of the
centralnervoussystem.Microglia aredistributedthroughout
the CNS and are continuously surveying the environment
with mobile arborizations of cell processes. Under normal
conditions, these cells have been called “resting microglia,”
the term recently questioned due to recognition that these
cells are actually continuously providing surveillance in the
nervous system [24]. They sense and react to many types
of damage, such as microbial infection, serum microhemor-
rhage of blood vessels, immunoglobulin-antigen complexes,
and abnormal proteins produced in the neurodegenerative
diseases. In response to such stimuli, microglia change their
morphology from ramiﬁed to amoeboid form, migrate to
the damaged cells, and subsequently clear the debris of
the dead cells. Through such processes, microglia release
reactiveoxygenspecies,proinﬂammatory cytokines,comple-
ment factors, and neurotoxic molecules, leading to further
neuronal dysfunction and death, which is a vicious cycle
called as neuroinﬂammation [25].
Gliosis has long been known as a component of ALS
pathology, with microgliosis recognized in the past 20
years [26, 27]. Further, recent work using positron emis-
sion tomography provided direct evidence of widespread
microglial activation in the brains of living ALS patients
[28]. The intensity of microglial activation was correlated
with severity of upper motor neuron damage, suggesting an
active involvement of microglial activation in the disease.
Extensive microgliosis and inﬂammation accompanied by
elevated level of proinﬂammatory cytokines are reproducibly
demonstrated in the lesion of mutant SOD1 transgenic
mice [22, 23]. Molecules released from activated microglia
include proinﬂammatory cytokines (tumor necrosis factor-
α,i n t e r l e u k i n - 1 β,i n t e r l e u k i n - 12, interferon-γ,a n do t h e r s ) ,
reactive oxygen species (superoxide, nitric oxide, and its
derivatives), chemokines and mitogenic factors (monocyte
chemoattractant protein 1, macrophage colony stimulating
factor), anti-inﬂammatory cytokines (tumor growth factor-
β), and neurotrophic factors (IGF-1: insulin-like growth
factor-1) [29–33].
A detrimental role of mutant SOD1 in microglia was
ﬁrst demonstrated in a cell culture system. Mutant SOD1-
expressing microgliareleasedhigherlevelsofTumorNecrosis
Factor-α and Interleukin-6 in comparison to the wild-type
microglia when stimulated with lipopolysaccharide (LPS)
[34]. Non-cell autonomous eﬀects of mutant microglia were
further conﬁrmed by showing reduced survival rates of
the primary cultured motor neurons when cocultured with
mutant microglia [35].
The active role of microglia in disease progression was
demonstrated by three independent experiments. Selective
reduction of mutant SOD1 from microglia/macrophages
in mice using Cre-Lox system demonstrated that mutant
toxicity within microglia slowed disease progression in
SOD1G37R [19] and SOD1G85R mice [20]. A complimentary
approach using replacing microglia/macrophage via bone
marrow transplantation reached the same conclusion and
demonstrated that wild-type microglia/macrophage slowed
disease progression in SOD1G93A mice [36].
The identity of factors that activate microglia has been
explored. The innate immune system is the ﬁrst line of
defense against invading pathogens which are recognized
mainly through toll-like receptors (TLRs). Elevated level
of innate immune receptors such as TLR2 and CD14 was
recorded in mutant SOD1 mice. Further, bone marrow
deﬁcient of MyD88 (myeloid diﬀerentiation factor 88),
essential adaptor protein to transmit most of TLR signaling,
accelerated disease progression in SOD1G37R mice [37].
This outcome is likely related to an eﬀect of irradiation in
the process of chimeric mice generation [38, 39]. Indeed,
gene deletion of MyD88 had no eﬀect on disease course
of SOD1G37R mice [37]. To date, factors known to be
released from damaged neurons in ALS models are ATP
and extracellular SOD1, which activate microglia in vitro
through purinergic receptors and CD14, respectively [40,
41]. Other factors central to damaged motor neuron-
microglial communication and the role of innate immune
system in ALS should be explored further.
In contrast to innate immune system, the role of
acquired immunity in ALS has recently been extensively
investigated. The presence of T lymphocyte in ALS mouse
models as well as sporadic ALS patients [42] suggested the
involvement of acquired immunity in ALS. Genetic ablation
of CD4+T cells or functional T cells (RAG2 gene deletion)
accelerated disease progression in ALS mice [43, 44]. In
those studies, presence of CD4+T cells was considered to
stabilize microglial activation status with decreased level
of proinﬂammatory cytokines and increase of neurotrophic
factor, IGF-1. Another recent study showed that transferringNeurology Research International 3
activated CD4+CD25+ cells extended life span of mutant
SOD1 mice [45]. These studies support a protective role
of speciﬁc population of T lymphocytes through controlled
microglial activation.
3.Astrocytes
Astrocytes have many important functions in maintaining
and nourishing central nervous system (CNS) neurons.
One of the main important functions is to maintain low
extracellular concentration of glutamate. Astrocytesclear the
excess of glutamate neurotransmitter from the synaptic clefts
mostly by employing EAAT2/GLT-1 glutamate transporter.
Overabundanceofglutamateleads toneuronal excitotoxicity
dueto excessive neuronal ﬁring and corresponding increased
inﬂux of calcium. Accumulating evidence demonstrates that
astrocytic function of clearing glutamate is impaired due
to a loss of EAAT2/GLT1 transporter in sporadic and
familial ALS human cases as well as SOD1 mouse models
[5, 46, 47]. Riluzole, a pharmacological agent that reduces
glutamate release from nerve terminals and is the only
currently clinically approved drug for ALS, supports the role
of excitotoxicity in ALS. Finally, mutant SOD1 astrocytes
secrete factors that lower the expression of the GluR2
glutamate receptor subunit, which results in more Ca2+
permeable AMPA receptors in motor neurons. However, if
mutant SOD1 astrocytes are not present, mutant SOD1 in
motor neurons does not have the same eﬀect, which again
shows non-cell autonomous death mechanisms in ALS [48].
A second role that can be attributed to deleterious
astrocyte behavior in ALS is an insuﬃcient release of
neurotrophic factors that are important in maintaining
neuronal health. Glial-derived neurotrophic factor, brain-
derived neurotrophic factor, ciliary neurotrophic factor,
and vascular endothelial growth factor are all released by
astrocytes and can rescue motor neurons [49, 50]. A loss
of neurotrophins if not directly, then indirectly, might be a
cause ofneuronal death.Inadditionto neurotrophins, astro-
cytes may release hazardous factors. In vitro studies conﬁrm
that factors released by SOD1 astrocytes in culture media
can induce apoptosis in motor neuron cultures. One of the
identiﬁed toxic factors is neurotrophic growth factor (NGF)
[51]. Similarly, wild-type embryonic stem (ES) cell-derived
motor neurons co-cultured with mutant SOD1-expressing
GFAP positive astrocytes are induced to degenerate and die
indicating non-cell autonomous degeneration mechanism
[52–55].
The role of astrocytes in ALS pathology has been widely
recognized and appreciated. Astrocytes have become an
interesting therapeutic target, and more new studies of inter-
vention are coming to light. The transcription factor, Nrf2,
regulates the expression of genes containing antioxidant
response element(ARE),which arepreferentiallyactivatedin
astrocytes. Anattempt to activate ARE/Nrf2 inastrocytes has
been successful in protecting neighboring neurons in vitro,
and extends the survival in ALS mice [56].
On the other hand, in one study where proliferating
astrocytes were a target of selective ablation, neither onset
nor progression ofdisease was aﬀectedinmutantSOD1mice
[57]. It has also been shown that ablation of astrocytes in
injury models does not help the outcome as the astrocytes
might play a protective role [58]. Incontrast, transplantation
of healthy glial precursor cells, which later diﬀerentiated
into astrocytes, proved to be neuroprotective and extended
survival time in mutant SOD1 model [59]. The beneﬁt of
transplanting healthy glial cells is in accordance with works
in which Cre-mediated ablation of mutant SOD1 transgenes
selectively from GFAP-positive astrocytes extended lifespan
of ALS mice [18, 21].
4.Oligodendrocytesand NG2 Cells
Microglia and astrocytes have been recognized as major
p l a y e r si nA L Sd i s e a s e .H o w e v e r ,o t h e rg l i a lc e l l ss u c ha s
NG2 cells (sometimes called synantocytes or pericytes) and
oligodendrocyteshave not been investigated to a large extent.
There are very few reports suggesting that these glial cells
might be involved in ALS pathogenesis. A study of human
ALS postmortem tissue showed diﬀuse myelin pallor in the
anterolateral columns associated with microglial inﬁltration
and loss in numberofsmall ﬁbersmost likelyduetointrinsic
spinal cord lesions [60]. A later study examined myelin
state in ALS in more detail and they found that myelin
abnormalities such as a loss of compact myelin, lamellae
detachment, and a decrease in lipid content were evident
in presymptomatic cords. More pronounced morphological
and biochemical myelin degeneration was evident in fully
symptomatic stages of mutant SOD1 rats [61]. It is too early
to speculate whether oligodendrocytes or myelin sheaths
have any role in ALS disease onset and progression, but the
few studies that examined the issue suggest that it might
be an interesting target for further study. In contrast, the
most recent study employing chimeric mice suggested that
oligodendrocytes might not be an important element in the
disease pathology. The researchers examined chimeric mice
whose all motor neurons and oligodendrocytes expressed
high levels of mutant SOD1. Disease onset was substan-
tially delayed in the mice suggesting non-cell autonomous
mechanism where cell types other than motor neurons and
oligodendrocytes must be major contributors to ALS disease
onset and perhaps progression [62].
NG2 cells (marked by nerve-glia factor 2 proteoglycan
antibody) have been very little examined in the context
of ALS pathology. NG2 cells are one of the ﬁrst cells to
respond to any changes in CNS environment. They assume
activated morphology and start dividing due to any insults
or disturbances to the CNS where they contribute to chang-
ing cellular environment with producing new astrocytes,
oligodendrocytes, and, in some areas of the CNS, neurons.
The ﬁrst report established an increased cell division asso-
ciated with the ALS disease progression and noticed that
a percentage of NG2 cells become astrocytes most likely
due to proinﬂammatory cytokine signaling [63]. However,
a very recent study demonstrated that the majority of NG2
cells remain committed to an oligodendrocyte lineage in
the adult wild-type mice as well as symptomatic SOD1G93A4 Neurology Research International
mice, suggesting that NG2 cells do not play a major role
in astrogliosis [64] .N G 2c e l l sm i g h tp a r t i c i p a t en o to n l yi n
contributingtoastrogliosisbutalsoinotheryetundiscovered
ways.Anotherreasonwhy itisimportant tounderstand NG2
cell role in ALS is that due to a regenerative capacity of these
cells they might be mobilized to generate cells, and secrete
factors conducive to beneﬁcial ALS outcome.
5.SchwannCells
Schwann cells—peripheral myelin generating cells—are
closely associated with motor neuron axons and aid the
axonal development and regeneration. So far, very little is
known about Schwann cell involvement in ALS pathology.
Studies of human ALS show peripheral myelin changes
along the motor neuron axons which are most likely due
to axonal degeneration [65]. Recent studies show limited or
unexpected Schwann cell involvement in the disease pro-
gression. One study expressed mutant SOD1G93A transgene
only in protein zero (P0) positive Schwann cells and these
mice were identical to control animals with no changes to
locomotion, neuronal loss, or axonal degeneration [66]. The
study demonstrates the lack of speciﬁc causal involvement
of myelinating P0 Schwann cells in the ALS disease onset or
progression. A second study used a diﬀerent approach, and,
instead of inducing higher synthesis of SOD1, they removed
mutant SOD1G37R from Schwann cells using Cre-mediated
gene excision. Surprisingly, the authors discovered that even
though disease onset was not altered, the disease progres-
sion was dramatically accelerated suggesting a connection
between disease progression in ALS and a protective eﬀect
of mutant SOD1G37R in Schwann cells. Finally, they observed
that reduced mutant SOD1 expression was associated with
diminished levels of insulin-like growth factor 1 [67]. A
close relationship between Schwann cells and motor neuron
axonswarrants more studiesto helpusbetterunderstand the
pathology of ALS.
6.Conclusionand Perspective
Active contributions of glial cells in ALS pathology have
recently been extensively demonstrated as reviewed here.
Finally, it should be well considered whether translating the
research results using SOD1rodent models into understand-
ing and development of treatment for sporadic ALS. To
date, several clinical trials using drugs targeting glial cells
were designed for sporadic ALS patients. These drugs were
proved to have eﬀect on mutant SOD1 mice. Antibiotics,
minocycline and cyclooxygenase 2 inhibitor, celecoxib, were
eﬀective to extend the survival for mutant SOD1 mice [68–
71].However,ALSpatientsdidnottolerateminocyclinewell,
and there was no evidence demonstrating slowing of the
disease in the phase III clinical trial [72]. A recent mouse
study, in which minocycline was administered after disease
onset exacerbated neuroinﬂammation, explains the failure of
human clinical trial [73]. Similarly, clinical trial of celecoxib
for sporadic ALS patients showed no eﬀect, although the
dose of celecoxib used for trial did not decrease the level of
Prostaglandin E(2) in CSF [74]. Failure to translate results of
rodent models to sporadic human patients was attributed to
several reasons [75].
First, in many preclinical studies, the drugs were admin-
istered to animals before onset. However, this is not the case
for sporadic ALS patients, since human patients are treated
after the diagnosis. Second, in many cases the drug eﬀects
aiming toextend thesurvival time ofmice were modest, with
cohortsizes thatwerenotsuﬃcientenough.Adequatecohort
size as well as the timing of initiating drug treatment should
be carefully considered in the rodent studies [76]. Third, the
disease mechanism of mutant SOD1-mediated familial ALS
could be diﬀerent from sporadic ALS. Recent discovery of
new genes, TDP-43, FUS, responsible for ALS has provided
new opportunity to the development of new animal models
[77, 78]. Newrodent models useful fortesting new candidate
drugs are awaited. Lastly, the molecules misregulated in the
glial cells in mutant SOD1-mediated ALS should be re-
evaluated in human sporadic ALS cases.
Controlling neuroinﬂammation and communication to
immune system have also been the focus in other neu-
rodegenerative diseases including Alzheimer’s and Parkin-
son’s diseases [79, 80]. Further understanding of molecular
pathology within glial cells will contribute to developing
therapies that will slow ALS disease progression beneﬁting
sporadic and familiar ALS patients.
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